Penumbra Inc. designs, develops, manufactures, and markets medical devices used in neurovascular, intensive care, and peripheral vascular interventions. Its technologies support treatment of a wide range of body and brain conditions, including acute ischemic stroke, brain aneurysms, neuro arteriovenous malformations, acute limb ischemia, deep vein thrombosis, pulmonary embolism, and other aneurysms.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Penumbra focuses on the development of new products and clinical activities designed to support the regulatory submissions and demonstrate the effectiveness of its products. The company has various R&D work progressed in therapy areas related to strokes, clots in veins and arteries. The company’s research and development activities are carried out in its facility at Alameda, California. In FY2025, the company spent US$89.7 million on its R&D activities, which as a percentage of revenue stood at 6.3% and declined 5.2% YoY. As of December 31, 2025, the company owned rights to 125 issued patents worldwide, of which 66 were US patents, and had rights to 49 pending patent applications, of which 21 were patent applications pending in the US. The company also had 46 US trademark registrations and 235 foreign trademark registrations as of December 31, 2025.